High levels of long term steroid use have unwanted side effects, howevera steroid sparing therapy (either reducing dose or frequency to alleviate theunwanted side effects) working synergistically with a utrophin upregulator, has thepotential to become the new standard of care for all DMD patients. The gene discussed is UTRN; the disease is Duchenne muscular dystrophy.